Get the Stockscreener App
1.55
1.97%
0.03
After Hours:
1.55
Compugen Ltd stock is traded at $1.55, with a volume of 260.77K.
It is up +1.97% in the last 24 hours and up +2.65% over the past month.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
See More
Previous Close:
$1.52
Open:
$1.54
24h Volume:
260.77K
Relative Volume:
0.62
Market Cap:
$144.98M
Revenue:
-
Net Income/Loss:
$1.60M
P/E Ratio:
51.67
EPS:
0.03
Net Cash Flow:
$-62.91M
1W Performance:
+4.73%
1M Performance:
+2.65%
6M Performance:
-11.93%
1Y Performance:
-3.13%
1-Day Range:
$1.54
$1.60
1-Week Range:
$1.46
$1.60
52-Week Range:
$1.13
$2.66
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
1.55 | 142.17M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Initiated | Oppenheimer | Outperform |
| Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
| May-26-20 | Resumed | JMP Securities | Mkt Outperform |
| May-13-20 | Initiated | Stifel | Buy |
| May-07-20 | Initiated | SVB Leerink | Outperform |
| Apr-22-20 | Initiated | ROTH Capital | Buy |
| Mar-24-20 | Initiated | SunTrust | Buy |
| Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-29-18 | Initiated | Oppenheimer | Outperform |
| Feb-01-16 | Resumed | Oppenheimer | Outperform |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Apr-23-15 | Resumed | Jefferies | Buy |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Feb-07-14 | Initiated | MLV & Co | Buy |
| Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
Is Compugen Ltd. stock a bargain at current levels2026 world cup usa national team third place match top scorers counter attacking knockout prediction preview - Улправда
Compugen rises on royalty deal with AstraZeneca - MSN
Operating cash flow per share of Compugen Ltd. – TASE:CGEN - TradingView — Track All Markets
Why Compugen Ltd. stock could benefit from AI revolutionMarket Sentiment Summary & Consistent Profit Trading Strategies - Улправда
Will Compugen Ltd. stock benefit from sector rotationWeekly Profit Summary & Daily Growth Stock Tips - Улправда
Is Compugen Ltd. stock a defensive play in 2025Portfolio Gains Summary & Real-Time Volume Analysis Alerts - Улправда
Can Compugen Ltd. stock deliver strong Q4 earningsJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - Улправда
Bull Run: Why Compugen Ltd. stock could benefit from AI revolutionJuly 2025 Reactions & Risk Controlled Stock Pick Alerts - Улправда
Compugen Secures $90 Million in a Strategic Royalty Monetization Deal with AstraZeneca - The Globe and Mail
Compugen shares jump after $65 million royalty monetization deal with AstraZeneca - MSN
Compugen (CGEN) Rises on Royalty Deal with AstraZeneca - GuruFocus
Compugen restructures AstraZeneca deal to boost cash coffers - גלובס
Compugen stock soars on $65 million AstraZeneca royalty deal By Investing.com - Investing.com Nigeria
Compugen stock soars on $65 million AstraZeneca royalty deal - Investing.com
Compugen Monetizes Portion of Cancer Treatment Future Royalties to AstraZeneca for Up to $90 Million - marketscreener.com
Compugen rises on royalty deal with AstraZeneca (CGEN:NASDAQ) - Seeking Alpha
Compugen monetizes portion of cancer drug royalties to AstraZeneca By Investing.com - Investing.com South Africa
Compugen monetizes portion of cancer drug royalties to AstraZeneca - Investing.com
Compugen monetizes portion of rilvegostomig future royalties to AstraZeneca for up to $90 million - marketscreener.com
Compugen Ltd. and Medimmune Limited Enter into Amendment Number 4 to the License Agreement - marketscreener.com
Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million - TradingView — Track All Markets
[6-K] COMPUGEN LTD Current Report (Foreign Issuer) | CGEN SEC FilingForm 6-K - Stock Titan
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million - marketscreener.com
Cancer immunotherapy royalty deal brings biotech up to $90M in funding - Stock Titan
Compugen secures $90 million in a strategic royalty monetization deal with AstraZeneca - MSN
Revenue per share of Compugen Ltd. – TASE:CGEN - TradingView — Track All Markets
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Compugen Presents Promising COM701 Analysis at ESMO 2025 - MSN
Compugen’s Former Head Reflects on Computational Discovery, Strategic Collaborations And AI - Citeline News & Insights
Compugen (NASDAQ:CGEN) Share Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Compugen Ltd (CGEN) Stock Price & 30 Year Financial Data - GuruFocus
Compugen (NASDAQ:CGEN) versus PepGen (NASDAQ:PEPG) Critical Review - Defense World
Can Compugen Ltd. stock beat analyst upgrades2025 Risk Factors & AI Based Buy and Sell Signals - newser.com
What indicators show strength in Compugen Ltd.Layoff News & Fast Momentum Entry Tips - newser.com
Is Compugen Ltd. stock oversold or undervaluedJuly 2025 Trade Ideas & Community Verified Trade Alerts - newser.com
What high frequency data says about Compugen Ltd.July 2025 Action & High Accuracy Trade Signal Alerts - newser.com
Real time social sentiment graph for Compugen Ltd.Portfolio Risk Report & Reliable Entry Point Trade Alerts - newser.com
How interest rate cuts could boost Compugen Ltd. stockQuarterly Market Summary & Verified Swing Trading Watchlist - newser.com
Is now a turning point for Compugen Ltd.Stock Surge & AI Driven Price Predictions - newser.com
Compugen Ltd Stock (CGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):